Atypical Antipsychotics During Pregnancy

Make decisions based on available evidence, individualized risk/benefit analysis

Thalia Robakis, MD, PhD
Clinical Instructor
Katherine E. Williams, MD
Clinical Associate Professor
Department of Psychiatry and Behavioral Science
Stanford University
Stanford, CA

Although clinicians and patients generally are cautious when prescribing or using antipsychotics during pregnancy, inadequately controlled psychiatric illness poses risks to both mother and child. Calculating the risks and benefits of antipsychotic use during pregnancy is limited by an incomplete understanding of the true effectiveness and full spectrum of risks of these medications. Ethical principles prohibit the type of rigorous research that would be needed to achieve clarity on this issue. This article reviews studies that might help guide clinicians who are considering prescribing an atypical antipsychotic to manage psychiatric illness in a pregnant woman.

Antipsychotic efficacy in pregnancy
All atypical antipsychotics available in the United States are FDA-approved for treating schizophrenia; some also have been approved for treating bipolar disorder, unipolar depression, or symptoms associated with autism (see this article at CurrentPsychiatry.com for a Table listing the approved indications). Atypical antipsychotics frequently are used off-label for these and other categories of psychiatric illness, including unipolar depression, generalized anxiety disorder, and obsessive-compulsive disorder.

Studies of pharmacotherapy in pregnant women tend to focus more on safety rather than efficacy. Clinical decisions for an individual patient are best made based on knowledge about which medications have been effective for that patient in the past (Algorithm, page 14). However, safety
Atypical antipsychotics and pregnancy

Clinical Point
To date, studies of atypical antipsychotics do not support any increased risk for congenital malformations

Discuss this article at www.facebook.com/CurrentPsychiatry

Risks of treatment vs illness
Complete safety data on the use of any psychotropic medication during pregnancy are not available. To date, studies of atypical antipsychotics do not support any increased risk for congenital malformations large enough to be detected in medium-sized samples, although it is possible that there are increases in risk that are below the detection limit of these studies. Data regarding delivery outcomes are conflicting and difficult to interpret.

Several studies have yielded inconsistent results, including:

- risks for increased birth weight and large for gestational age
- risks for low birth weight and small for gestational age
- no significant differences from controls

Atypical antipsychotics increase the risk of gestational diabetes, whereas typical antipsychotics do not appear to increase this risk.

Until recently, research has been limited by difficulties in separating the effects of treatment from the effects of psychiatric illness, which include intrauterine growth retardation, prematurity, preterm birth, low Apgar scores, and congenital defects. In addition, most studies address early and easily measurable outcomes such as preterm labor, birth weight, and congenital malformations. Researchers are just beginning to investigate more subtle and long-term potential behavioral effects.

Several recent studies have explored outcomes associated with antipsychotic use during pregnancy while attempting to
Antipsychotic metabolism during pregnancy

Pregnancy is associated with an increased volume of distribution, decreased concentration of plasma proteins, increased hepatic function, and hormone-induced changes in metabolic enzymes that may alter medication's efficacy. Although no studies have focused on changes in antipsychotic metabolism and dose adjustments in pregnancy, it is likely that antipsychotics' effectiveness is affected by pregnancy.

The activity of the cytochrome P450 (CYP) isozymes CYP2D6, CYP3A4, and CYP2C9 are increased during pregnancy, whereas the activities of CYP1A2 and CYP2C19 are decreased. Changes in liver metabolism with pregnancy might contribute to decreased serum levels of risperidone, aripiprazole, and olanzapine, which are metabolized by CYP2D6, and to increased serum levels of clozapine and olanzapine, which are principally metabolized by CYP3A4. Studies of changes in CYP2A6, the major metabolizing enzyme for quetiapine and lurasidone—have yielded variable results but suggest possible increases in drug clearance during the third trimester.

Increased hepatic blood flow and volume of distribution and decreased concentrations of plasma binding proteins act non-specifically; the former decrease serum concentrations of blood-borne substances, and the latter increases them.

Data on atypicals

Aripiprazole. Case reports of aripiprazole use during pregnancy have reported difficulties including transient unexplained fetal tachycardia that required emergent caesarean section and transient respiratory distress. Several small case series were not powered to detect risks related to aripiprazole.

Animal data suggest teratogenic potential at dosages 3 and 10 times the maximum recommended human dose. Two studies that measured placental transfer of aripiprazole found cord-to-maternal serum concentration ratios ranging from 0.47 to 0.63, which is similar to the ratios for quetiapine and risperidone and lower than those for olanzapine and haloperidol.

There are insufficient data to identify risks related to aripiprazole compared with other drugs in its class, and fewer reports are available than for other atypical antipsychotics such as quetiapine and olanzapine. Placental transfer appears to be on the lower end of the spectrum for drugs in this class. Aripiprazole would be an acceptable choice for a woman who had a history of response to aripiprazole but likely would not be a first choice for a woman requiring a new medication during pregnancy.

Clozapine. In case reports, adverse effects associated with clozapine exposure during pregnancy include major malformations, gestational metabolic complications, poor pregnancy outcome, and perinatal adverse reactions. In one case, neonatal plasma clozapine concentrations were found to be twice that found in maternal plasma. Animal data have shown no evidence of increased teratogenicity at 2 to 4 times the maximum recommended human doses. Boden et al found an increased risk for gestational diabetes and macrocephaly with clozapine (11 exposures). Four other series were underpowered to detect concerns related specifically to clozapine.

There are insufficient data to identify risks related specifically to clozapine use during pregnancy. However, the rare but severe adverse effects associated with clozapine in other patient populations—including agranulocytosis and severe constipation—could be devastating in a pregnant patient, which suggests this medication would not be a first-line treatment.

Olanzapine. In postmarketing surveillance studies and case reports, there have been have anecdotal cases of fetal malformations related to olanzapine use during pregnancy. Several larger studies did not find higher rates of congenital malformations or any pattern of malformation.
Psychiatric illness during pregnancy: Risks of antipsychotics vs risk of no treatment

In several studies, researchers have attempted to compare the risks of antipsychotic use during pregnancy with the risk of untreated psychiatric illness. Lin et al. examined registry data of 686 mothers with schizophrenia and 3,480 matched controls. The infants of 464 women with schizophrenia who did not take antipsychotics had an elevated risk for low birth weight and small for gestational age, but not for preterm birth or large for gestational age compared with infants of women without schizophrenia. Women with schizophrenia who were treated with atypical antipsychotics (n = 48) did not separate on any measure from untreated women with schizophrenia, although 95% confidence intervals were large and overlapped with those of the control group.

Women treated with typical antipsychotics (n = 194) had a significantly elevated rate of preterm birth compared with untreated women with schizophrenia. This finding was the study's only reliable outcome; it was insufficiently powered to detect differences between treated, untreated, and non-psychotic women for other outcomes. Furthermore, researchers did not control for maternal smoking, alcohol and other substance use, pre-pregnancy body mass index, or nutritional status, and medication adherence was not evaluated. This study highlights the potential morbidity associated with untreated mental illness in pregnancy, and supports a reduction in gestational age at birth with the use of first-generation—but not second-generation—antipsychotics.

Boden et al. examined registry data of 169 women taking olanzapine and/or clozapine, 338 women taking other antipsychotics (218 taking atypical and 120 taking typical), and 357,696 women taking no antipsychotics during pregnancy. Both groups of women taking antipsychotics had nearly doubled odds of gestational diabetes. However, the only outcome that showed a significant post-adjustment difference was macrocephaly, for which the olanzapine/clozapine group showed an odds ratio of 3.2 while the other antipsychotics group showed no significant difference from controls. This study also found an increase in preterm births for the other antipsychotics group.

In an investigation of neuromotor outcomes, researchers compared 212 mother-infant pairs with in utero exposure to antipsychotics (n = 22) or antidepressants (n = 202) to pairs receiving no psychotropics (n = 85). They found a reduction in mean scores at age 6 months on the Infant Neurological International Battery (INFANIB) (mean 63.86, standard deviation [SD] 1.78 for the antipsychotic group and mean 70.12, SD 1.03 for controls) after controlling for multiple factors, including maternal psychiatric history. However, the study was small and, despite the difference in the means, the scatter plot showed similar score ranges for the antipsychotic-treated and control groups. Because there are no normative data available for the INFANIB, the clinical significance of these results is difficult to assess. This study highlights the need for further investigations with larger sample sizes but is reassuring in that the neurological battery score ranges for antipsychotic-exposed and control infants were substantially similar.

Source: For reference citations, see this article at CurrentPsychiatry.com

Types, although none were designed or powered to examine rare events. Animal data show no evidence of teratogenicity. A study comparing rates of placental passage of antipsychotics found higher rates for olanzapine than for quetiapine and risperidone, as well as higher prevalence of low birth weight and perinatal complications. A neonatal withdrawal syndrome has also been reported. Boden et al. found an increased risk for gestational diabetes and macrocephaly with olanzapine.

Data suggest that olanzapine may be associated with somewhat higher rates of the adverse effects attributable to atypical antipsychotics (gestational diabetes and possibly macrocephaly), which could be related to olanzapine's relatively higher rate of placental passage. Olanzapine could be a reasonable choice in a woman who had a history of good response to this medication, but would be lower priority than quetiapine when a new drug is indicated during pregnancy.

Quetiapine. In clinical trials, quetiapine had lower rates of placental passage compared with risperidone and olanzapine. One case report found only small changes in quetiapine serum levels during pregnancy. Prospective studies (90 exposures, 36 exposures, 7 exposures, 4 exposures, and 4 exposures) show no increase in fetal malformations or adverse neonatal health
outcomes related to quetiapine, and manufacturer safety data reveal no teratogenic effect, although delays in fetal skeletal ossification were seen in rats and rabbits at doses comparable to the recommended human range.21

Quetiapine is a reasonable first choice when a new atypical antipsychotic is indicated for a pregnant patient.

Risperidone. Rates of placental passage of risperidone are higher compared with quetiapine.13 Postmarketing surveillance data (265 exposures22 and 10 exposures23) and prospective studies (including 72 exposures,5 49 exposures,2 51 exposures,3 16 exposures,16 and 5 exposures5) suggest risperidone has no major teratogenic effect. When malformations were present, they were similar to expected rates and types of malformations, and no specific malformation type was overrepresented. However, in some cases, researchers noted a withdrawal-emergent syndrome that included various combinations of tremors, irritability, poor feeding, and somnolence.22 Animal data are similarly reassuring, although increases in early fetal mortality and (potentially related) changes in maternal behavior have been observed in rats.24,25 A major caveat with risperidone is its propensity to cause hyperprolactinemia, which is detrimental to efforts to conceive and maintain a pregnancy.26,27

Risperidone is not associated with higher rates of adverse events in pregnancy than other atypical antipsychotics. It would not be a first choice for a woman trying to conceive or in the early stages of pregnancy, but would be a reasonable choice for a woman already well into pregnancy.

Ziprasidone. Available reports are few and generally do not report findings on ziprasidone separately.8,28 Manufacturer data include 5 spontaneous abortions, one malformation, and one stillbirth among 175 exposures,2 and available animal data suggest significant developmental toxicity and impaired fertility.29 In pregnant rats, ziprasidone dosed as low as 0.5 times the maximum human recommended dose resulted in delayed fetal skeletal ossification, increased stillbirths, and decreased fetal weight and postnatal survival, and ziprasidone dosed as low as 0.2 times the maximum recommended human dose resulted in developmental delays and neurobehavioral impairments in offspring. In pregnant rabbits, ziprasidone dosed at 3 times the maximum recommended human dose resulted in cardiac and renal malformations.29

Although available data are too sparse to draw reliable conclusions, the small amount of human data plus animal data suggest that ziprasidone should be less preferred than other atypical antipsychotics during pregnancy.

Lurasidone. No data addressing lurasidone use in humans during pregnancy are available. Material submitted to the FDA includes no evidence of teratogenicity or embryo-fetal toxicity in rat and rabbit studies using 3 and 12 times the maximum recommended human dose (80 mg) based on a body surface area comparison.30

Asenapine. No data specifically addressing asenapine use in humans during pregnancy are available. Studies in rats and rabbits found no increase in teratogenicity, but did find increases in postimplantation loss and decreases in pup survival and weight gain with maternal doses equivalent to less than the maximum recommended human dose.31

Iloperidone. No data specifically addressing iloperidone use in humans during pregnancy are available. Animal studies of iloperidone found multiple developmental toxicities when iloperidone was administered during gestation.32 In one study, pregnant rats were given up to 26 times the maximum recommended human dose of 24 mg/d during the period of organogenesis. The highest dose caused increased early intrauterine deaths, decreased fetal weight and length, decreased fetal skeletal ossification, and increased minor fetal skeletal anomalies and variations. In a similar study using pregnant rabbits, the highest dose caused increased early intrauterine deaths and decreased fetal viability at term.

Clinical Point
In clinical trials, quetiapine had lower rates of placental passage compared with risperidone and olanzapine.
Atypical antipsychotics, and pregnancy

Clinical Point

Atypicals could trigger or worsen glucose intolerance, which can have significant negative consequences in a pregnant patient.

Paliperidone. In animal studies, there were no increases in fetal abnormalities when pregnant rats and rabbits were treated with up to 8 times the maximum recommended human dose of paliperidone during the period of organogenesis.30

A single case report34 measured levels of risperidone and its 9-hydroxy metabolite, paliperidone, in the breast milk of a mother who had taken risperidone during pregnancy and in the serum of her child. 9-OH-risperidone dose in breast milk was calculated as 4.7% of the weight-adjusted maternal dose, and serum levels in the infant were undetectable. No ill effects on the child were observed.

It is not possible to draw solid conclusions about atypical antipsychotics’ potential effects on human development from animal studies. Because of the lack of human data for the newer atypical antipsychotics—aripiprazole, iloperidone, lurasidone, paliperidone—in general these agents would not be advisable as first-line medications for treating pregnant women.

A few caveats

All atypical antipsychotics share the propensity to trigger or worsen glucose intolerance, which can have significant negative consequences in a pregnant patient. When deciding to use an atypical antipsychotic during pregnancy, blood glucose should be monitored carefully and regularly. For a Box that discusses diabetes, antipsychotics, and pregnancy and a Table outlining monitoring recommendations, see this article at CurrentPsychiatry.com.

Because all atypical antipsychotics (except clozapine) are FDA pregnancy class C—indicating that animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks—the decision to use these medications must be based on an individualized assessment of risks and benefits. Patients and their providers together should make a fully informed decision.

There is an urgent need for larger and better-designed investigations that will be sufficiently powered to detect differences in outcomes—particularly major malformations, preterm delivery, adverse events in labor and delivery, metabolic and anthropometric effects on the newborn, and neurodevelopmental and psychiatric outcomes for individuals exposed in utero—between women without mental illness, untreated women with mental illness, and women receiving atypical antipsychotics during pregnancy. Further research into the pharmacokinetics and clinical efficacy of antipsychotics in pregnant women also would be useful. Clinicians can assist with these efforts by submitting their patient data to a pregnancy registry maintained by the Massachusetts General Hospital (see Related Resources).

References